Johnson & Johnson Logo

Johnson & Johnson

JNJ

(2.8)
Stock Price

144,47 USD

39.15% ROA

20.94% ROE

10.11x PER

Market Cap.

384.412.155.600,00 USD

58% DER

3.82% Yield

16.74% NPM

Johnson & Johnson Stock Analysis

Johnson & Johnson Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Johnson & Johnson Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (47.1%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a minimal amount of debt (42%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend Growth

Investors can take confidence in the company's impressive track record of annual dividend growth over the last five years, showcasing a commitment to rewarding shareholders.

5 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (988) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (5.06x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

11 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Johnson & Johnson Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Johnson & Johnson Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Johnson & Johnson Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Johnson & Johnson Revenue
Year Revenue Growth
1985 6.421.300.000
1986 7.002.900.000 8.31%
1987 8.012.000.000 12.59%
1988 9.000.000.000 10.98%
1989 9.757.000.000 7.76%
1990 11.232.000.000 13.13%
1991 12.447.000.000 9.76%
1992 13.753.000.000 9.5%
1993 14.138.000.000 2.72%
1994 15.734.000.000 10.14%
1995 18.842.000.000 16.5%
1996 21.620.000.000 12.85%
1997 22.629.000.000 4.46%
1998 23.657.000.000 4.35%
1999 27.471.000.000 13.88%
2000 29.139.000.000 5.72%
2001 33.004.000.000 11.71%
2002 36.298.000.000 9.07%
2003 41.862.000.000 13.29%
2004 47.348.000.000 11.59%
2005 50.514.000.000 6.27%
2006 53.324.000.000 5.27%
2007 61.095.000.000 12.72%
2008 63.747.000.000 4.16%
2009 61.897.000.000 -2.99%
2010 61.587.000.000 -0.5%
2011 65.030.000.000 5.29%
2012 67.224.000.000 3.26%
2013 71.312.000.000 5.73%
2014 74.331.000.000 4.06%
2015 70.074.000.000 -6.08%
2016 71.890.000.000 2.53%
2017 76.450.000.000 5.96%
2018 81.581.000.000 6.29%
2019 82.059.000.000 0.58%
2020 82.584.000.000 0.64%
2021 78.740.000.000 -4.88%
2022 79.990.000.000 1.56%
2023 85.404.000.000 6.34%
2023 85.159.000.000 -0.29%
2024 89.788.000.000 5.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Johnson & Johnson Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 1.278.000.000 100%
1995 0 0%
1996 0 0%
1997 2.140.000.000 100%
1998 2.269.000.000 5.69%
1999 2.600.000.000 12.73%
2000 2.926.000.000 11.14%
2001 3.591.000.000 18.52%
2002 3.957.000.000 9.25%
2003 4.684.000.000 15.52%
2004 5.203.000.000 9.98%
2005 6.312.000.000 17.57%
2006 7.125.000.000 11.41%
2007 7.680.000.000 7.23%
2008 7.758.000.000 1.01%
2009 7.167.000.000 -8.25%
2010 6.844.000.000 -4.72%
2011 7.548.000.000 9.33%
2012 7.665.000.000 1.53%
2013 8.183.000.000 6.33%
2014 8.494.000.000 3.66%
2015 9.046.000.000 6.1%
2016 9.095.000.000 0.54%
2017 10.554.000.000 13.82%
2018 10.775.000.000 2.05%
2019 11.355.000.000 5.11%
2020 12.340.000.000 7.98%
2021 14.277.000.000 13.57%
2022 14.135.000.000 -1%
2023 13.788.000.000 -2.52%
2023 15.085.000.000 8.6%
2024 13.760.000.000 -9.63%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Johnson & Johnson General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 22.084.000.000 100%
2021 20.118.000.000 -9.77%
2022 19.046.000.000 -5.63%
2023 0 0%
2023 20.112.000.000 100%
2024 21.924.000.000 8.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Johnson & Johnson EBITDA
Year EBITDA Growth
1985 985.400.000
1986 1.786.000.000 44.83%
1987 1.465.000.000 -21.91%
1988 1.699.000.000 13.77%
1989 2.081.000.000 18.36%
1990 2.634.000.000 20.99%
1991 2.654.000.000 0.75%
1992 2.783.000.000 4.64%
1993 2.931.000.000 5.05%
1994 3.575.000.000 18.01%
1995 4.419.000.000 19.1%
1996 5.457.000.000 19.02%
1997 5.615.000.000 2.81%
1998 6.957.000.000 19.29%
1999 7.592.000.000 8.36%
2000 8.080.000.000 6.04%
2001 9.780.000.000 17.38%
2002 11.823.000.000 17.28%
2003 13.273.000.000 10.92%
2004 15.020.000.000 11.63%
2005 15.612.000.000 3.79%
2006 15.774.000.000 1.03%
2007 20.076.000.000 21.43%
2008 17.748.000.000 -13.12%
2009 17.029.000.000 -4.22%
2010 16.527.000.000 -3.04%
2011 19.465.000.000 15.09%
2012 18.195.000.000 -6.98%
2013 19.537.000.000 6.87%
2014 21.315.000.000 8.34%
2015 19.022.000.000 -12.05%
2016 21.685.000.000 12.28%
2017 19.839.000.000 -9.3%
2018 22.552.000.000 12.03%
2019 22.126.000.000 -1.93%
2020 24.176.000.000 8.48%
2021 27.860.000.000 13.22%
2022 30.163.000.000 7.64%
2023 25.048.000.000 -20.42%
2023 32.322.000.000 22.5%
2024 37.124.000.000 12.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Johnson & Johnson Gross Profit
Year Gross Profit Growth
1985 4.077.600.000
1986 4.648.000.000 12.27%
1987 5.410.000.000 14.09%
1988 6.099.000.000 11.3%
1989 6.691.000.000 8.85%
1990 7.769.000.000 13.88%
1991 8.736.000.000 11.07%
1992 9.635.000.000 9.33%
1993 9.964.000.000 3.3%
1994 11.159.000.000 10.71%
1995 13.464.000.000 17.12%
1996 15.611.000.000 13.75%
1997 16.544.000.000 5.64%
1998 17.467.000.000 5.28%
1999 20.473.000.000 14.68%
2000 21.793.000.000 6.06%
2001 23.468.000.000 7.14%
2002 25.851.000.000 9.22%
2003 29.686.000.000 12.92%
2004 33.926.000.000 12.5%
2005 36.560.000.000 7.2%
2006 38.267.000.000 4.46%
2007 43.344.000.000 11.71%
2008 45.236.000.000 4.18%
2009 43.450.000.000 -4.11%
2010 42.795.000.000 -1.53%
2011 44.670.000.000 4.2%
2012 45.566.000.000 1.97%
2013 48.970.000.000 6.95%
2014 51.585.000.000 5.07%
2015 48.538.000.000 -6.28%
2016 50.205.000.000 3.32%
2017 51.096.000.000 1.74%
2018 54.490.000.000 6.23%
2019 54.503.000.000 0.02%
2020 54.157.000.000 -0.64%
2021 55.338.000.000 2.13%
2022 55.394.000.000 0.1%
2023 58.980.000.000 6.08%
2023 58.606.000.000 -0.64%
2024 62.312.000.000 5.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Johnson & Johnson Net Profit
Year Net Profit Growth
1985 613.700.000
1986 329.500.000 -86.25%
1987 833.000.000 60.44%
1988 974.000.000 14.48%
1989 1.082.000.000 9.98%
1990 1.143.000.000 5.34%
1991 1.461.000.000 21.77%
1992 1.030.000.000 -41.84%
1993 1.787.000.000 42.36%
1994 2.006.000.000 10.92%
1995 2.403.000.000 16.52%
1996 2.887.000.000 16.76%
1997 3.303.000.000 12.59%
1998 3.059.000.000 -7.98%
1999 4.167.000.000 26.59%
2000 4.800.000.000 13.19%
2001 5.668.000.000 15.31%
2002 6.597.000.000 14.08%
2003 7.197.000.000 8.34%
2004 8.509.000.000 15.42%
2005 10.411.000.000 18.27%
2006 11.053.000.000 5.81%
2007 10.576.000.000 -4.51%
2008 12.949.000.000 18.33%
2009 12.266.000.000 -5.57%
2010 13.334.000.000 8.01%
2011 9.672.000.000 -37.86%
2012 10.853.000.000 10.88%
2013 13.831.000.000 21.53%
2014 16.323.000.000 15.27%
2015 15.409.000.000 -5.93%
2016 16.540.000.000 6.84%
2017 1.300.000.000 -1172.31%
2018 15.297.000.000 91.5%
2019 15.119.000.000 -1.18%
2020 14.714.000.000 -2.75%
2021 20.878.000.000 29.52%
2022 17.941.000.000 -16.37%
2023 104.112.000.000 82.77%
2023 35.153.000.000 -196.17%
2024 18.744.000.000 -87.54%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Johnson & Johnson Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 1 0%
1992 0 0%
1993 1 0%
1994 1 0%
1995 1 0%
1996 1 100%
1997 1 0%
1998 1 0%
1999 1 0%
2000 2 0%
2001 2 0%
2002 2 50%
2003 2 0%
2004 3 0%
2005 3 33.33%
2006 4 0%
2007 4 0%
2008 5 25%
2009 4 0%
2010 5 0%
2011 4 -33.33%
2012 4 0%
2013 5 25%
2014 6 20%
2015 6 0%
2016 6 16.67%
2017 0 0%
2018 6 100%
2019 6 0%
2020 6 0%
2021 8 28.57%
2022 7 -16.67%
2023 43 86.05%
2023 14 -230.77%
2024 8 -85.71%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Johnson & Johnson Free Cashflow
Year Free Cashflow Growth
1989 500.000.000
1990 827.000.000 39.54%
1991 688.000.000 -20.2%
1992 1.038.000.000 33.72%
1993 1.193.000.000 12.99%
1994 2.038.000.000 41.46%
1995 2.126.000.000 4.14%
1996 2.518.000.000 15.57%
1997 2.952.000.000 14.7%
1998 -55.000.000 5467.27%
1999 3.678.000.000 101.5%
2000 4.917.000.000 25.2%
2001 7.133.000.000 31.07%
2002 6.077.000.000 -17.38%
2003 8.333.000.000 27.07%
2004 8.956.000.000 6.96%
2005 9.245.000.000 3.13%
2006 11.510.000.000 19.68%
2007 11.939.000.000 3.59%
2008 11.906.000.000 -0.28%
2009 14.206.000.000 16.19%
2010 14.001.000.000 -1.46%
2011 11.405.000.000 -22.76%
2012 12.462.000.000 8.48%
2013 13.819.000.000 9.82%
2014 14.757.000.000 6.36%
2015 15.816.000.000 6.7%
2016 15.541.000.000 -1.77%
2017 17.777.000.000 12.58%
2018 18.531.000.000 4.07%
2019 19.918.000.000 6.96%
2020 20.189.000.000 1.34%
2021 19.758.000.000 -2.18%
2022 17.185.000.000 -14.97%
2023 6.522.000.000 -163.49%
2023 18.248.000.000 64.26%
2024 4.657.000.000 -291.84%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Johnson & Johnson Operating Cashflow
Year Operating Cashflow Growth
1989 1.250.000.000
1990 1.657.000.000 24.56%
1991 1.675.000.000 1.07%
1992 2.141.000.000 21.77%
1993 2.168.000.000 1.25%
1994 2.975.000.000 27.13%
1995 3.382.000.000 12.03%
1996 3.891.000.000 13.08%
1997 4.343.000.000 10.41%
1998 4.886.000.000 11.11%
1999 5.677.000.000 13.93%
2000 6.563.000.000 13.5%
2001 8.864.000.000 25.96%
2002 8.176.000.000 -8.41%
2003 10.595.000.000 22.83%
2004 11.131.000.000 4.82%
2005 11.877.000.000 6.28%
2006 14.248.000.000 16.64%
2007 15.249.000.000 6.56%
2008 14.972.000.000 -1.85%
2009 16.571.000.000 9.65%
2010 16.385.000.000 -1.14%
2011 14.298.000.000 -14.6%
2012 15.396.000.000 7.13%
2013 17.414.000.000 11.59%
2014 18.471.000.000 5.72%
2015 19.279.000.000 4.19%
2016 18.767.000.000 -2.73%
2017 21.056.000.000 10.87%
2018 22.201.000.000 5.16%
2019 23.416.000.000 5.19%
2020 23.536.000.000 0.51%
2021 23.410.000.000 -0.54%
2022 21.194.000.000 -10.46%
2023 7.489.000.000 -183%
2023 22.791.000.000 67.14%
2024 5.633.000.000 -304.6%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Johnson & Johnson Capital Expenditure
Year Capital Expenditure Growth
1989 750.000.000
1990 830.000.000 9.64%
1991 987.000.000 15.91%
1992 1.103.000.000 10.52%
1993 975.000.000 -13.13%
1994 937.000.000 -4.06%
1995 1.256.000.000 25.4%
1996 1.373.000.000 8.52%
1997 1.391.000.000 1.29%
1998 4.941.000.000 71.85%
1999 1.999.000.000 -147.17%
2000 1.646.000.000 -21.45%
2001 1.731.000.000 4.91%
2002 2.099.000.000 17.53%
2003 2.262.000.000 7.21%
2004 2.175.000.000 -4%
2005 2.632.000.000 17.36%
2006 2.738.000.000 3.87%
2007 3.310.000.000 17.28%
2008 3.066.000.000 -7.96%
2009 2.365.000.000 -29.64%
2010 2.384.000.000 0.8%
2011 2.893.000.000 17.59%
2012 2.934.000.000 1.4%
2013 3.595.000.000 18.39%
2014 3.714.000.000 3.2%
2015 3.463.000.000 -7.25%
2016 3.226.000.000 -7.35%
2017 3.279.000.000 1.62%
2018 3.670.000.000 10.65%
2019 3.498.000.000 -4.92%
2020 3.347.000.000 -4.51%
2021 3.652.000.000 8.35%
2022 4.009.000.000 8.9%
2023 967.000.000 -314.58%
2023 4.543.000.000 78.71%
2024 976.000.000 -365.47%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Johnson & Johnson Equity
Year Equity Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 59.752.000.000 100%
2019 59.471.000.000 -0.47%
2020 63.278.000.000 6.02%
2021 74.023.000.000 14.52%
2022 76.804.000.000 3.62%
2023 68.774.000.000 -11.68%
2023 71.228.000.000 3.45%
2024 71.538.000.000 0.43%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Johnson & Johnson Assets
Year Assets Growth
1985 5.095.100.000
1986 5.876.700.000 13.3%
1987 6.546.000.000 10.22%
1988 7.119.000.000 8.05%
1989 7.919.000.000 10.1%
1990 9.506.000.000 16.69%
1991 10.513.000.000 9.58%
1992 11.884.000.000 11.54%
1993 12.242.000.000 2.92%
1994 15.668.000.000 21.87%
1995 17.873.000.000 12.34%
1996 20.010.000.000 10.68%
1997 21.453.000.000 6.73%
1998 26.211.000.000 18.15%
1999 29.163.000.000 10.12%
2000 31.321.000.000 6.89%
2001 38.488.000.000 18.62%
2002 40.556.000.000 5.1%
2003 48.263.000.000 15.97%
2004 53.317.000.000 9.48%
2005 58.025.000.000 8.11%
2006 70.556.000.000 17.76%
2007 80.954.000.000 12.84%
2008 84.912.000.000 4.66%
2009 94.682.000.000 10.32%
2010 102.908.000.000 7.99%
2011 113.644.000.000 9.45%
2012 121.347.000.000 6.35%
2013 132.683.000.000 8.54%
2014 130.358.000.000 -1.78%
2015 133.411.000.000 2.29%
2016 141.208.000.000 5.52%
2017 157.303.000.000 10.23%
2018 152.954.000.000 -2.84%
2019 157.728.000.000 3.03%
2020 174.894.000.000 9.82%
2021 182.018.000.000 3.91%
2022 187.378.000.000 2.86%
2023 167.558.000.000 -11.83%
2023 166.061.000.000 -0.9%
2024 181.088.000.000 8.3%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Johnson & Johnson Liabilities
Year Liabilities Growth
1985 1.744.200.000
1986 3.052.500.000 42.86%
1987 3.061.000.000 0.28%
1988 3.616.000.000 15.35%
1989 3.771.000.000 4.11%
1990 4.606.000.000 18.13%
1991 4.887.000.000 5.75%
1992 6.713.000.000 27.2%
1993 6.674.000.000 -0.58%
1994 8.546.000.000 21.9%
1995 8.828.000.000 3.19%
1996 9.174.000.000 3.77%
1997 9.094.000.000 -0.88%
1998 12.621.000.000 27.95%
1999 12.950.000.000 2.54%
2000 12.513.000.000 -3.49%
2001 14.255.000.000 12.22%
2002 17.859.000.000 20.18%
2003 21.394.000.000 16.52%
2004 21.504.000.000 0.51%
2005 20.154.000.000 -6.7%
2006 31.238.000.000 35.48%
2007 37.635.000.000 17%
2008 42.401.000.000 11.24%
2009 44.094.000.000 3.84%
2010 46.329.000.000 4.82%
2011 56.564.000.000 18.09%
2012 56.521.000.000 -0.08%
2013 58.630.000.000 3.6%
2014 61.367.000.000 4.46%
2015 62.261.000.000 1.44%
2016 70.790.000.000 12.05%
2017 97.143.000.000 27.13%
2018 93.202.000.000 -4.23%
2019 98.257.000.000 5.14%
2020 111.616.000.000 11.97%
2021 107.995.000.000 -3.35%
2022 110.574.000.000 2.33%
2023 98.784.000.000 -11.94%
2023 94.833.000.000 -4.17%
2024 109.550.000.000 13.43%

Johnson & Johnson Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
35.97
Net Income per Share
15.8
Price to Earning Ratio
10.11x
Price To Sales Ratio
4.44x
POCF Ratio
15.6
PFCF Ratio
18.93
Price to Book Ratio
5.37
EV to Sales
4.63
EV Over EBITDA
12.02
EV to Operating CashFlow
16.27
EV to FreeCashFlow
19.75
Earnings Yield
0.1
FreeCashFlow Yield
0.05
Market Cap
384,41 Bil.
Enterprise Value
401,03 Bil.
Graham Number
102.78
Graham NetNet
-27.48

Income Statement Metrics

Net Income per Share
15.8
Income Quality
1.5
ROE
0.54
Return On Assets
0.08
Return On Capital Employed
0.17
Net Income per EBT
0.83
EBT Per Ebit
0.8
Ebit per Revenue
0.25
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
0.24
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.69
Operating Profit Margin
0.25
Pretax Profit Margin
0.2
Net Profit Margin
0.17

Dividends

Dividend Yield
0.04
Dividend Yield %
3.82
Payout Ratio
0.3
Dividend Per Share
6.1

Operating Metrics

Operating Cashflow per Share
10.24
Free CashFlow per Share
8.44
Capex to Operating CashFlow
0.18
Capex to Revenue
0.05
Capex to Depreciation
0.6
Return on Invested Capital
0.19
Return on Tangible Assets
0.39
Days Sales Outstanding
66.59
Days Payables Outstanding
120.58
Days of Inventory on Hand
165.83
Receivables Turnover
5.48
Payables Turnover
3.03
Inventory Turnover
2.2
Capex per Share
1.8

Balance Sheet

Cash per Share
10,58
Book Value per Share
29,72
Tangible Book Value per Share
-5.17
Shareholders Equity per Share
29.72
Interest Debt per Share
17.56
Debt to Equity
0.58
Debt to Assets
0.23
Net Debt to EBITDA
0.5
Current Ratio
1.07
Tangible Asset Value
-12,44 Bil.
Net Current Asset Value
-51,73 Bil.
Invested Capital
107607000000
Working Capital
3,88 Bil.
Intangibles to Total Assets
0.46
Average Receivables
15,37 Bil.
Average Payables
8,51 Bil.
Average Inventory
11776000000
Debt to Market Cap
0.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Johnson & Johnson Dividends
Year Dividends Growth
1970 1
1971 0 0%
1972 0 0%
1973 1 0%
1974 1 0%
1975 1 0%
1976 1 100%
1977 1 0%
1978 2 0%
1979 2 50%
1980 2 0%
1981 1 -100%
1982 1 0%
1983 1 100%
1984 1 0%
1985 1 0%
1986 1 0%
1987 2 0%
1988 2 0%
1989 1 0%
1990 1 0%
1991 2 0%
1992 1 0%
1993 1 0%
1994 1 0%
1995 1 0%
1996 1 0%
1997 1 0%
1998 1 0%
1999 1 100%
2000 1 0%
2001 1 0%
2002 1 0%
2003 1 0%
2004 1 100%
2005 1 0%
2006 1 0%
2007 2 0%
2008 2 0%
2009 2 0%
2010 2 50%
2011 2 0%
2012 2 0%
2013 3 0%
2014 3 0%
2015 3 0%
2016 3 33.33%
2017 3 0%
2018 4 0%
2019 4 0%
2020 4 0%
2021 4 25%
2022 4 0%
2023 5 0%
2024 4 -33.33%

Johnson & Johnson Profile

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

CEO
Mr. Joaquin Duato
Employee
131.900
Address
One Johnson & Johnson Plaza
New Brunswick, 08933

Johnson & Johnson Executives & BODs

Johnson & Johnson Executives & BODs
# Name Age
1 Mr. James Swanson
Executive Vice President & Chief Information Officer
70
2 Ms. Jessica Moore
Vice President of Investor Relations
70
3 Ms. Jennifer L. Taubert
Executive Vice President & Worldwide Chairman of Innovative Medicine
70
4 Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer
70
5 Mr. Joseph J. Wolk CPA
Executive Vice President & Chief Financial Officer
70
6 Mr. Dirk Brinckman
Chief Compliance Officer
70
7 Ms. Elizabeth Forminard J.D.
Executive Vice President & Chief Legal Officer
70
8 Dr. Guy J. Lebeau M.D.
Group Chairman of MD&D Business - EMEA
70
9 Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Innovative Medicine, R&D
70
10 Mr. Joaquin Duato
Chief Executive Officer & Chairman
70

Johnson & Johnson Competitors

Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
Amgen Inc. Logo
Amgen Inc.

AMGN

(3.2)
Pfizer Inc. Logo
Pfizer Inc.

PFE

(2.5)
AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)